| Literature DB >> 29201163 |
Hong Xiao1, Lihua Yang2, Jianjun Liu3,4, Yang Jiao3,4, Lin Lu3,4, Hongbo Zhao3,4.
Abstract
The identification of biomarkers and their interaction network involved in the processes of endometriosis is a critical step in understanding the underlying mechanisms of the disease. The aim of the present study was to construct biomarker networks of endometriosis that integrated human protein-protein interactions and known disease-causing genes. Endometriosis-associated genes were extracted from Genotator and DisGeNet and biomarker network and pathway analyses were constructed using atBioNet. Of 100 input genes, 96 were strongly mapped to six major modules. The majority of the pathways in the first module were associated with the proliferation of cancer cells, the enriched pathways in module B were associated with the immune system and infectious diseases, module C included pathways related to immune and metastasis, the enriched pathways in module D were associated with inflammatory processes, and the majority of the pathways in module E were related to replication and repair. The present approach identified known and potential biomarkers in endometriosis. The identified biomarker networks are highly enriched in biological pathways associated with endometriosis, which may provide further insight into the molecular mechanisms underlying endometriosis.Entities:
Keywords: biomarker; endometriosis; module; network; protein-protein interaction
Year: 2017 PMID: 29201163 PMCID: PMC5704338 DOI: 10.3892/etm.2017.5185
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.Network constructed from endometriosis-associated genes. Squares represent seed genes and circles represent added genes. (A-F) represent modules A-F, respectively.
Hub genes in each module.
| Module | Gene ID | Gene symbol |
|---|---|---|
| A | 196 | AHR |
| A | 367 | AR |
| A | 405 | ARNT |
| A | 2099 | ESR1 |
| A | 8204 | NRIP1 |
| A | 2100 | ESR2 |
| A | 7157 | TP53 |
| A | 2516 | NR5A1 |
| A | 2908 | NR3C1 |
| A | 5241 | PGR |
| B | 3557 | IL1RN |
| B | 3552 | IL1A |
| B | 3554 | IL1R1 |
| B | 3553 | IL1B |
| B | 3560 | IL2RB |
| B | 3600 | IL15 |
| B | 3565 | IL4 |
| B | 3586 | IL10 |
| B | 3606 | IL18 |
| C | 4316 | MMP7 |
| C | 3479 | IGF1 |
| C | 3484 | IGFBP1 |
| C | 4312 | MMP1 |
| C | 5069 | PAPPA |
| C | 7077 | TIMP2 |
| C | 4322 | MMP13 |
| C | 4321 | MMP12 |
| D | 3106 | HLA-B |
| D | 3105 | HLA-A |
| D | 3107 | HLA-C |
| D | 3115 | HLA-DPB1 |
| D | 3117 | HLA-DQA1 |
| D | 3119 | HLA-DQB1 |
| D | 3123 | HLA-DRB1 |
| E | 328 | APEX1 |
| E | 4968 | OGG1 |
| E | 7515 | XRCC1 |
| E | 2068 | ERCC2 |
| E | 2073 | ERCC5 |
| F | 355 | FAS |
| F | 356 | FASLG |
| F | 7132 | TNFRSF1A |
| F | 7124 | TNF |
| F | 4049 | LTA |
Top 10 KEGG pathways ranked by P-value for the top six modules in endometriosis.
| Functional modules (no. of genes) | Map title in KEGG | No. of genes mapped in the pathway | P-value[ |
|---|---|---|---|
| Module A (n=42) | Pathways in cancer (hsa05200) | 7 | <0.0001 |
| Thyroid cancer (hsa05216) | 3 | <0.0001 | |
| Prostate cancer (hsa05215) | 4 | 0.0001 | |
| Oocyte meiosis (hsa04114) | 4 | 0.0003 | |
| Neurotrophin signaling pathway (hsa04722) | 4 | 0.0005 | |
| Cell cycle (hsa04110) | 4 | 0.0005 | |
| Basal transcription factors (hsa03022) | 3 | 0.0005 | |
| Colorectal cancer (hsa05210) | 3 | 0.0008 | |
| Wnt signaling pathway (hsa04310) | 4 | 0.0009 | |
| Renal cell carcinoma (hsa05211) | 3 | 0.0011 | |
| Module B (n=54) | Cytokine-cytokine receptor interaction (hsa04060) | 19 | <0.0001 |
| Apoptosis (hsa04210) | 11 | <0.0001 | |
| JAK-STAT signaling pathway (hsa04630) | 15 | <0.0001 | |
| Pertussis (hsa05133) | 9 | <0.0001 | |
| Measles (hsa05162) | 11 | <0.0001 | |
| Tuberculosis (hsa05152) | 11 | <0.0001 | |
| Toxoplasmosis (hsa05145) | 9 | <0.0001 | |
| Leishmaniasis (hsa05140) | 7 | <0.0001 | |
| Intestinal immune network for IgA production (hsa04672) | 6 | <0.0001 | |
| Toll-like receptor signaling pathway (hsa04620) | 7 | <0.0001 | |
| Module C (n=60) | Complement and coagulation cascades (hsa04610) | 6 | <0.0001 |
| Hypertrophic cardiomyopathy (hsa05410) | 4 | 0.0009 | |
| ECM-receptor interaction (hsa04512) | 4 | 0.0010 | |
| Dilated cardiomyopathy (hsa05414) | 4 | 0.0012 | |
| Hematopoietic cell lineage (hsa04640) | 3 | 0.0111 | |
| Focal adhesion (hsa04510) | 4 | 0.0208 | |
| Proteasome (hsa03050) | 2 | 0.0237 | |
| Pathways in cancer (hsa05200) | 5 | 0.0280 | |
| Vitamin B6 metabolism (hsa00750) | 1 | 0.0316 | |
| Staphylococcus aureus infection (hsa05150) | 2 | 0.0355 | |
| Module D (n=87) | Phagosome (hsa04145) | 17 | <0.0001 |
| Cell adhesion molecules (hsa04514) | 24 | <0.0001 | |
| Antigen processing and presentation (hsa04612) | 24 | <0.0001 | |
| Natural killer cell mediated cytotoxicity (hsa04650) | 13 | <0.0001 | |
| T cell receptor signaling pathway (hsa04660) | 18 | <0.0001 | |
| Intestinal immune network for IgA production (hsa04672) | 13 | <0.0001 | |
| Type I diabetes mellitus (hsa04940) | 17 | <0.0001 | |
| Leishmaniasis (hsa05140) | 14 | <0.0001 | |
| Toxoplasmosis (hsa05145) | 13 | <0.0001 | |
| Staphylococcus aureus infection (hsa05150) | 13 | <0.0001 | |
| Module E (n=87) | Purine metabolism (hsa00230) | 19 | <0.0001 |
| Pyrimidine metabolism (hsa00240) | 19 | <0.0001 | |
| RNA polymerase (hsa03020) | 12 | <0.0001 | |
| DNA replication (hsa03030) | 17 | <0.0001 | |
| Base excision repair (hsa03410) | 22 | <0.0001 | |
| Nucleotide excision repair (hsa03420) | 31 | <0.0001 | |
| Mismatch repair (hsa03430) | 14 | <0.0001 | |
| Homologous recombination (hsa03440) | 7 | <0.0001 | |
| Huntington's disease (hsa05016) | 13 | <0.0001 | |
| Basal transcription factors (hsa03022) | 6 | <0.0001 | |
| Module F (n=38) | Cytokine-cytokine receptor interaction (hsa04060) | 12 | <0.0001 |
| Apoptosis (hsa04210) | 14 | <0.0001 | |
| RIG-I-like receptor signaling pathway (hsa04622) | 7 | <0.0001 | |
| Tuberculosis (hsa05152) | 8 | <0.0001 | |
| Pathways in cancer (hsa05200) | 10 | <0.0001 | |
| Natural killer cell mediated cytotoxicity (hsa04650) | 7 | <0.0001 | |
| Chagas disease (American trypanosomiasis; hsa05142) | 6 | <0.0001 | |
| Alzheimer's disease (hsa05010) | 7 | <0.0001 | |
| Osteoclast differentiation (hsa04380) | 6 | <0.0001 | |
| Type I diabetes mellitus (hsa04940) | 4 | <0.0001 |
According to Fisher's exact test. KEGG, Kyoto Encyclopedia of Genes and Genomes; JAK-STAT, Janus kinase-signal transducer and activator of transcription; IgA, immunoglobulin A; ECM, extracellular matrix.
Figure 2.Known and potential endometriosis biomarkers found by protein-protein interaction. The (A) first and (B) second modules are shown. Red circles represent seed genes and blue/grey circles represent the identified endometriosis biomarker genes, based on the seed genes with blue circles being confirmed by literature and grey circles representing currently unconfirmed biomarker genes.
Details of the 15 potential endometriosis biomarkers in modules A and B demonstrated in literature.
| Gene ID | Gene symbol | Module | PMID | Description |
|---|---|---|---|---|
| 1051 | CEBPB | A | 23097472 | A novel functional link between C/EBPβ and STAT3 that is a critical regulator of endometrial differentiation in women. |
| 1499 | CTNNB1 | A | 23765252 | CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade endometrial endometrioid carcinomas (28%; P<0.0057). |
| 2289 | FKBP5 | A | 22279148 | No significant endometriosis-related change was observed for FKBP5. |
| 6908 | TBP | A | 18252806 | TBP inhibits the TNF-α-induced expression of endome triotic genes in 12Z endometriotic epithelial cells. |
| 10499 | NCOA2 | A | 12050280 | Abnormal increases in endometrial TIF2 and SRC-3 levels are also associated with infertility in women with polycystic ovary syndrome. |
| 6657 | SOX2 | A | 23670619 | Samples from endometriosis patients had higher mRNA expression levels of Oct-4, CXCR4, SOX2 and MET compared with that of the normal controls. |
| 6662 | SOX9 | A | 23847113 | Cells in ectopic endometriosis lesions also expressed SSEA-1 and nuclear SOX9. |
| 2 | A2M | B | 2454848 | Women with endometriosis had significantly lower amounts of functional α-2M than did women without endometriosis. |
| 836 | CASP3 | B | 24246915 | Significantly lower expression of caspase-3 protein was found in ectopic (3.20±1.24) and eutopic endometrium (3.88±1.93) as compared with the control group (6.49±1.85; P<0.01). |
| 7189 | TRAF6 | B | 20130413 | TRAF2, TRAF6 and TAK1 were constitutively activated and were unaffected by TSA treatment in endometriotic cells. |
| 834 | CASP1 | B | 17094974 | Eutopic and ectopic ECs from women with endome triosis expressed decreased transcript abundance of p53 and Caspase-1 compared to ECs from women without endometriosis. |
| 6284 | S100A13 | B | 15821778 | Expression of S100A13 corresponds to the activation of the endothelial cells in the process of endometriotic angiogenesis. |
| 7850 | IL1R2 | B | 17482186 | IL-1RII can neutralize IL-1β and counteract its effect on endometrial stromal cells, and may provide a new clinical strategy for the treatment of endometriosis. |
| 3561 | IL2RG | B | 16759924 | IL2RG was demonstrated to be significantly differen tially expressed in blood lymphocytes between endome triosis patients and controls. |
| 3718 | JAK3 | B | 17631002 | JAK3 inhibitors, especially JANEX-1, may prove useful to prevent or alleviate the symptoms of endometriosis. |
CEBPB, CCAAT/enhancer binding protein β; CTNNB1, catenin β 1; FKBP5, FK506 binding protein 5; TBP, TATA-box binding protein; NCOA2, nuclear receptor coactivator 2; SOX2, SRY-box 2; SOX9, SRY-box 9; A2M, α-2-macroglobulin; CASP3, caspase 3; TRAF6, TNF receptor associated factor 6; CASP1, caspase 1; S100A13, S100 calcium binding protein A13; IL1R2, interleukin 1 receptor type 2; IL2RG, interleukin 2 receptor subunit gamma; JAK3, Janus kinase 3.